Nextgen Biomed Statistics
Total Valuation
Nextgen Biomed has a market cap or net worth of ILS 6.82 million. The enterprise value is 6.74 million.
Market Cap | 6.82M |
Enterprise Value | 6.74M |
Important Dates
The next estimated earnings date is Thursday, November 28, 2024.
Earnings Date | Nov 28, 2024 |
Ex-Dividend Date | n/a |
Share Statistics
Nextgen Biomed has 9.66 million shares outstanding. The number of shares has increased by 3.65% in one year.
Current Share Class | n/a |
Shares Outstanding | 9.66M |
Shares Change (YoY) | +3.65% |
Shares Change (QoQ) | +4.82% |
Owned by Insiders (%) | 7.39% |
Owned by Institutions (%) | n/a |
Float | 8.95M |
Valuation Ratios
PE Ratio | n/a |
Forward PE | n/a |
PS Ratio | n/a |
PB Ratio | n/a |
P/TBV Ratio | n/a |
P/FCF Ratio | n/a |
P/OCF Ratio | n/a |
PEG Ratio | n/a |
Enterprise Valuation
EV / Earnings | -0.49 |
EV / Sales | n/a |
EV / EBITDA | n/a |
EV / EBIT | n/a |
EV / FCF | -2.21 |
Financial Position
The company has a current ratio of 0.16
Current Ratio | 0.16 |
Quick Ratio | 0.15 |
Debt / Equity | n/a |
Debt / EBITDA | n/a |
Debt / FCF | -0.08 |
Interest Coverage | -120.30 |
Financial Efficiency
Return on equity (ROE) is -341.38% and return on invested capital (ROIC) is -72.09%.
Return on Equity (ROE) | -341.38% |
Return on Assets (ROA) | -44.10% |
Return on Capital (ROIC) | -72.09% |
Revenue Per Employee | n/a |
Profits Per Employee | -2.76M |
Employee Count | 5 |
Asset Turnover | n/a |
Inventory Turnover | n/a |
Taxes
Income Tax | n/a |
Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -62.55% in the last 52 weeks. The beta is 0.85, so Nextgen Biomed's price volatility has been lower than the market average.
Beta (5Y) | 0.85 |
52-Week Price Change | -62.55% |
50-Day Moving Average | 70.46 |
200-Day Moving Average | 110.06 |
Relative Strength Index (RSI) | 36.66 |
Average Volume (20 Days) | 17,431 |
Short Selling Information
Short Interest | n/a |
Short Previous Month | n/a |
Short % of Shares Out | n/a |
Short % of Float | n/a |
Short Ratio (days to cover) | n/a |
Income Statement
Revenue | n/a |
Gross Profit | n/a |
Operating Income | -4.81M |
Pretax Income | -13.82M |
Net Income | -13.81M |
EBITDA | -4.79M |
EBIT | -4.81M |
Earnings Per Share (EPS) | -1.85 |
Balance Sheet
The company has 210,000 in cash and 248,000 in debt, giving a net cash position of -38,000 or -0.00 per share.
Cash & Cash Equivalents | 210,000 |
Total Debt | 248,000 |
Net Cash | -38,000 |
Net Cash Per Share | -0.00 |
Equity (Book Value) | -2.06M |
Book Value Per Share | -0.25 |
Working Capital | -2.29M |
Cash Flow
In the last 12 months, operating cash flow was -2.95 million and capital expenditures -100,000, giving a free cash flow of -3.05 million.
Operating Cash Flow | -2.95M |
Capital Expenditures | -100,000 |
Free Cash Flow | -3.05M |
FCF Per Share | -0.32 |
Margins
Gross Margin | n/a |
Operating Margin | n/a |
Pretax Margin | n/a |
Profit Margin | n/a |
EBITDA Margin | n/a |
EBIT Margin | n/a |
FCF Margin | n/a |
Dividends & Yields
Nextgen Biomed does not appear to pay any dividends at this time.
Dividend Per Share | n/a |
Dividend Yield | n/a |
Dividend Growth (YoY) | n/a |
Years of Dividend Growth | n/a |
Payout Ratio | n/a |
Buyback Yield | -3.65% |
Shareholder Yield | -3.65% |
Earnings Yield | n/a |
FCF Yield | n/a |
Stock Splits
The last stock split was on September 3, 2023. It was a reverse split with a ratio of 0.1666666667.
Last Split Date | Sep 3, 2023 |
Split Type | Reverse |
Split Ratio | 0.1666666667 |
Scores
Altman Z-Score | n/a |
Piotroski F-Score | n/a |